Neuropeptide Changes in Inflammatory Bowel Disease — VIP Down, Substance P Receptors Up
VIP is diminished in intestinal smooth muscle of Crohn's patients while substance P receptors are markedly increased — neuropeptide changes may actively drive IBD symptoms beyond simple inflammation.
Quick Facts
What This Study Found
VIP is diminished in intestinal smooth muscle of Crohn's patients. Substance P receptors are markedly increased at small vessels and lymph nodules in inflamed IBD intestine.
Key Numbers
How They Did This
Review of studies examining gut neuropeptide content, innervation patterns, and receptor distribution in tissue from IBD patients.
Why This Research Matters
If neuropeptides actively drive IBD symptoms like abnormal gut motility and inflammation, they could be targets for new treatments that go beyond standard immune suppression.
The Bigger Picture
If neuropeptide changes actively drive IBD symptoms, they represent therapeutic targets beyond standard immune suppression. This concept has influenced the development of peptide-targeted therapies for IBD and other gut disorders.
What This Study Doesn't Tell Us
Review article summarizing available evidence as of 1991. The field was still early, and not all findings had been replicated. Neuropeptide measurement techniques were evolving.
Questions This Raises
- ?Could VIP replacement therapy improve Crohn's motility symptoms?
- ?Are substance P receptor antagonists useful for IBD treatment?
Trust & Context
- Key Stat:
- VIP down, substance P receptors up Key neuropeptide changes in IBD that may actively drive abnormal motility, pain, and vascular changes
- Evidence Grade:
- Moderate-quality review synthesizing available evidence from tissue studies. Individual studies had varying quality.
- Study Age:
- Published in 1991. Neuropeptide involvement in IBD has been extensively confirmed and expanded since.
- Original Title:
- Neuropeptides and inflammatory bowel disease.
- Published In:
- Zeitschrift fur Gastroenterologie. Verhandlungsband, 26, 253-7 (1991)
- Authors:
- Eysselein, V E, Nast, C C
- Database ID:
- RPEP-00193
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is VIP and why does its loss matter in IBD?
VIP (vasoactive intestinal peptide) helps gut smooth muscle relax and promotes blood flow. Its loss in Crohn's disease may contribute to abnormal gut motility and impaired healing.
Could treating neuropeptide changes help IBD patients?
Potentially. If neuropeptide changes actively drive symptoms, targeting them with VIP analogs or substance P blockers could address motility, pain, and vascular symptoms that current immune suppressants may not fully control.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00193APA
Eysselein, V E; Nast, C C. (1991). Neuropeptides and inflammatory bowel disease.. Zeitschrift fur Gastroenterologie. Verhandlungsband, 26, 253-7.
MLA
Eysselein, V E, et al. "Neuropeptides and inflammatory bowel disease.." Zeitschrift fur Gastroenterologie. Verhandlungsband, 1991.
RethinkPeptides
RethinkPeptides Research Database. "Neuropeptides and inflammatory bowel disease." RPEP-00193. Retrieved from https://rethinkpeptides.com/research/eysselein-1991-neuropeptides-and-inflammatory-bowel
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.